Safety and feasibility of fasting in combination with platinum-based chemotherapy (2016)

Peer-Reviewed Study · Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI · June 10, 2016

Dorff TB et al., 2016-06-10: Dose-escalation study of 24, 48 and 72-hour fasting before platinum chemotherapy in 20 patients: fasting was feasible, fasting-related toxicity was grade 2 or less, grade 3-4 neutropenia events still occurred, and neutropenia showed a non-significant trend in favour of longer fasts.

Fasting for 72 h around chemotherapy administration is safe and feasible for cancer patients.

Abstract, Results and Conclusion

Dorff TB et al., 2016-06-10: Dose-escalation study of 24, 48 and 72-hour fasting before platinum chemotherapy in 20 patients: fasting was feasible, fasting-related toxicity was grade 2 or less, grade 3-4 neutropenia events still occurred, and neutropenia showed a non-significant trend in favour of longer fasts. Safety and feasibility only; no response or survival endpoint and no control arm. Funded by the V Foundation and NCI P30CA014089. Comparator: none (single-arm dose escalation across fasting durations). Study type: uncontrolled series.